Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse alveolar hemorrhage syndromes.

U Specks1

  • 1Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. specks.ulrich@mayo.edu

Current Opinion in Rheumatology
|January 10, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.

Clinical and experimental rheumatology·2015
Same author

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Arthritis & rheumatology (Hoboken, N.J.)·2015
Same author

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis & rheumatology (Hoboken, N.J.)·2014
Same author

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis and rheumatism·2013
Same author

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Arthritis and rheumatism·2012
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Diffuse alveolar hemorrhage (DAH) is a rare, life-threatening condition often linked to autoimmune diseases. Early diagnosis and treatment, including immunosuppression, are vital for patient survival.

Area of Science:

  • Pulmonary Medicine
  • Critical Care Medicine
  • Rheumatology

Background:

  • Diffuse alveolar hemorrhage (DAH) is a rare, severe, and potentially fatal complication.
  • It can arise from coagulation issues, toxic inhalations, or infections.
  • Autoimmune conditions like vasculitis and lupus erythematosus are common causes of DAH.

Purpose of the Study:

  • To offer a structured diagnostic and management strategy for DAH.
  • To consolidate current knowledge by reviewing recent and older publications.
  • To aid clinicians in managing patients with DAH.

Main Methods:

  • Comprehensive literature review of recent publications.
  • Synthesis of information from older case series and reports.
  • Focus on diagnostic criteria and therapeutic interventions.

Related Experiment Videos

Main Results:

  • DAH is frequently associated with capillaritis in systemic autoimmune diseases.
  • Prompt supportive care and immunosuppressive therapy are critical for survival.
  • Current management strategies are largely based on empirical data.

Conclusions:

  • Early recognition and intervention are paramount in DAH management.
  • A rational approach combining supportive and immunosuppressive therapies is essential.
  • This review provides an updated framework for DAH diagnosis and treatment.